Eswatini

Population 2018

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>3.7 (2.9–4.7)</td>
<td>229 (252–416)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>2.5 (1.9–3.1)</td>
<td>166 (166–275)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.36 (0.25–0.5)</td>
<td>32 (22–44)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.14 (0.089–0.2)</td>
<td>12 (7.8–18)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.51 (0.35–0.69)</td>
<td>45 (31–61)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis: 75%
- % with known HIV status: 99%
- % pulmonary: 88%
- % bacteriologically confirmed: 72%
- % children aged 0-14 years: 6%
- % women: 40%
- % men: 54%

Total cases notified: 3 151

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 80% (63–100)
- TB patients facing catastrophic total costs: 18% (12–24)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 18% (12–24)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 100%
  - New cases: 100%
  - Previously treated cases: 100%

Laboratory-confirmed cases*

- MDR/RR-TB: 182, XDR-TB: 10

Patients started on treatment**

- MDR/RR-TB: 149, XDR-TB: 10

MDR/RR-TB cases tested for resistance to second-line drugs: 154

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 86% (3 042)
- Previously treated cases, excluding relapse, registered in 2017: 77% (88)
- HIV-positive TB cases registered in 2017: 85% (2 150)
- MDR/RR-TB cases started on second-line treatment in 2016: 72% (2 356)
- XDR-TB cases started on second-line treatment in 2016: 65% (3 717)

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 12% (11–14)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 12% (11–14)

TB financing, 2019

- National TB budget (US$ millions): 12
- Funding source: 17% domestic, 83% international, 0% unfunded

* Ranges represent uncertainty intervals
* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
* Calculated for pulmonary cases only
** Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-01-03
Data: www.who.int/tb/data